India:
Cadila Healthcare, a leading pharmaceutical company in India, has
rebranded itself as Zydus Lifesciences Ltd. with an aim to create a new brand
identity. Zydus also launched a new brand logo that brings together two hearts,
one in purple symbolizing dedication to care and nurturance while the other
heart in teal color represents dynamism. The ‘us’ in the Zydus logo signifies
the stakeholders, including employees, health care providers, associates,
business partners, banks, investors, and all those involved in the company.
Building on a rich legacy of over 70 years, the rebranding of Cadila Healthcare
is a part of the company’s commitment to constantly evolve and unlock the
possibilities with life-changing discoveries to impact lives and empower
people.
Zydus
has made many first-in-India and first-in-world discoveries in the last seven
decades. It was the first Indian pharmaceutical company to make a breakthrough
in its research efforts with Lipaglyn, a novel drug for type-2 diabetes
treatment. Zydus has collaborated with Medicines for Malaria Venture (MMV) to
develop ZY19489, a potential fast-acting, single dose cure for the treatment of
malaria. Apart from being the first company to bring NCE from lab to market,
Zydus also has a robust pipeline for Biologics and Vaccines. The company has
recently started supplying the world’s first Plasmid DNA vaccine, ZyCoV-D, for
human use to the government.
In
March 2022, Zydus Lifesciences received approval for Oxemia, the
first-of-its-kind oral treatment in India for anemia associated with chronic
kidney disease, from the Drug Controller General of India (DCGI). Chronic
kidney disorders are likely to become one of the most common causes of
premature deaths in India by 2040.
Bringing
forth a new vision for the company, Zydus Lifesciences' Managing Director
commented, “Our new brand identity is a confluence of what we truly are. A
global lifesciences company driven by the purpose of delivering care and
nurturance for the patients, backed by the power of innovation, science, and cutting-edge
technology. With these attributes close to our heart, we wish to make a
meaningful difference in serving patients and communities. These pillars of
care, compassion and commitment to innovation will remain at the heart of all
that Zydus stands for.”
Commenting
on the rebranding of Cadila Healthcare, Director at TechSci Research Pvt. Ltd.
said, “Cadila Healthcare has remained among the leading players in India and
has played a crucial role in taking Indian pharma space to new global heights.
The company has constantly been improving its in-house new drug development
with an objective to launch new blockbusters. Many breakthrough developments by
Zydus have put Indian companies in direct competition with global innovators,
and the company will continue to excel in strengthening the Indian pharma
industry.”
According
to TechSci Research report on “India
E Pharmacy Market By Drug Type (Prescription Drugs v/s Over the Counter
(OTC) Drugs), By Product Type (Chronic Diseases, Skincare, Nutritional
Supplements, Medical Equipment, Others), By Operating Platform (Website v/s
Apps), By Business Model (Inventory/Warehouse Based Model v/s Market Place
Based Model), By Region, Competition Forecast & Opportunities, FY2027F”,
India e-pharmacy market is expected to witness a robust growth during the
forecast period. The growth can be attributed to the rising internet
penetration and growing awareness among population regarding health and
wellness.
According to another TechSci
Research report on “India Active
Pharmaceutical Ingredients Market By Method of Synthesis (Synthetic v/s Biological),
By Source (Contact Manufacturing Organizations v/s In-house Manufacturing), By
Therapeutic Application (Cardiovascular Diseases, Anti-diabetic Drugs, Oncology
Drugs, Neurological Disorders, Musculoskeletal Disorders, Others), By Drug Type
(Generics v/s Innovator), By Region, Competition Forecast & Opportunities,
FY2027”, India
active pharmaceutical ingredient market is expected to reach USD11.8 billion
during forecast period. The growth can be attributed to the factors like
increasing geriatric population and growing prevalence of cardiovascular
diseases.